A rapid stability indicating LC-method for determination of praziquantel in presence of its pharmacopoeial impurities

被引:13
作者
Hashem, Hisham [1 ,2 ]
Ibrahim, Adel Ehab [3 ]
Elhenawee, Magda [1 ]
机构
[1] Zagazig Univ, Pharmaceut Analyt Chem Dept, Fac Pharm, Zagazig, Egypt
[2] Jazan Univ, Pharmaceut Chem Dept, Fac Pharm, Jizan, Saudi Arabia
[3] Egyptian Int Pharmaceut Ind Co EIPICo, Tenth Ramadan City, Egypt
关键词
Praziquantel; Stress degradation; Stability indicating HPLC method; Pharmacopoeial impurities; LIQUID-CHROMATOGRAPHY; SCHISTOSOMIASIS;
D O I
10.1016/j.arabjc.2012.07.005
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This study reports for the first time about a stability indicating RP-HPLC method for quantitative determination of Praziquantel (PZQ) in bulk powder and dosage form and in presence of its pharmacopoeial impurities. The chromatographic separation was carried out on (Caltrex AI (R)) calixarene column, a relatively new packing material. Chromatography was done using an isocratic binary mobile phase consisting of ACN and 25 mM ammonium acetate (NH4Ac) in the ratio of 40: 60 at flow rate of 1 mL min(-1), 30 degrees C and 210 nm wavelength for detection. The elution time of PZQ was found to be 6.15 +/- 0.03 min. The method was validated for system suitability, linearity, precision, limits of detection and quantitation, specificity, stability and robustness. The robustness study was done for small changes in temperature, flow rate, wavelength of detection and% of ACN in mobile phase. Stability tests were done through exposure of the analyte solution to five different stress conditions: Reflux with 1 N HCl, reflux with 1 N NaOH, reflux with 30% H2O2, thermal degradation of powder and exposure to UV radiation. Limits of detection and quantification were found to be 0.56 and 1.70 mu g mL(-1), respectively. The recovery value of this method was 100.30% +/- 1.10 and the reproducibility was within 1.31. (C) 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University.
引用
收藏
页码:S35 / S41
页数:7
相关论文
共 16 条
[1]  
[Anonymous], 2011, US PHARMACOPOEIA 32
[2]  
Anurak C., 2004, J PHARM BIOMED ANAL, V36, P871
[3]   Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years' experience [J].
Chen, MG .
ACTA TROPICA, 2005, 96 (2-3) :168-176
[4]   Epidemiology, burden and control of schistosomiasis with particular consideration to past and current treatment trends [J].
Fenwick, Alan ;
Keiser, Jennifer ;
Utzinger, Jurg .
DRUGS OF THE FUTURE, 2006, 31 (05) :413-425
[5]   Optimisation of an HPLC method for the simultaneous determination of pyrantel pamoate, praziquantel, fenbendazole, oxfendazole and butylhydroxyanisole using a phenyl stationary phase [J].
Havlikova, Lucie ;
Brabcova, Ivana ;
Satinsky, Dalibor ;
Matysova, Ludmila ;
Luskacova, Alena ;
Osicka, Zdenek ;
Solich, Petr .
ANALYTICAL METHODS, 2012, 4 (06) :1592-1597
[6]  
Jia L., 2007, J PHARM BIOMED ANAL, V45, P263
[7]  
Jiangeng H., 2010, DRUG METAB PHARMACOK, V25, P487
[8]  
Kulik A, 2011, ACTA POL PHARM, V68, P467
[9]  
Putter J, 1979, Eur J Drug Metab Pharmacokinet, V4, P193
[10]  
Putter J, 1979, Eur J Drug Metab Pharmacokinet, V4, P143